Conavi Medical ( (TSE:CNVI) ) just unveiled an update.
Conavi Medical Corp. has announced an increase in its public offering of common shares and pre-funded warrants, with the proceeds aimed at advancing the development and pre-clinical testing of its Novasight 3.0 technology. This move is expected to strengthen Conavi’s position in the medical imaging industry, as the company plans to seek FDA clearance for its new technology in 2025, while also using the funds for working capital and general corporate purposes.
More about Conavi Medical
Conavi Medical is a commercial stage medical device company specializing in imaging technologies for minimally invasive cardiovascular procedures. Their flagship product, the Novasight Hybrid System, combines intravascular ultrasound and optical coherence tomography for enhanced imaging of coronary arteries, with regulatory approvals in the U.S., Canada, China, and Japan.
YTD Price Performance: -2.22%
Average Trading Volume: 4,932
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $8.43M
For an in-depth examination of CNVI stock, go to TipRanks’ Stock Analysis page.